Log In
Print
BCIQ
Print
Print this Print this
 

serlopitant (VPD-737) (formerly MK-0594)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionNeurokinin 1 (NK1) Substance P receptor (TACR1) antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationItch
Indication DetailsTreat chronic pruritus; Treat prurigo nodularis
Regulatory Designation

Partner

Tigercat Pharma Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today